Regeneron Pharmaceuticals Inc

14 nov. 2026, 01:02 UTC

Regeneron Pharmaceuticals, Inc. is trading modestly higher in after-hours following a recovery from an earlier session dip, near the upper end of its one-month range.

13 nov. 2026, 23:02 UTC

Regeneron Pharmaceuticals, Inc. shares are modestly higher in after-market trading following Friday's close, maintaining strong performance above its 20-day moving average.

12 nov. 2026, 21:07 UTC

Regeneron Pharmaceuticals, Inc. shares fell sharply after reaching an early peak, stabilizing near the upper end of its one-month range.

11 nov. 2026, 22:51 UTC

Regeneron Pharmaceuticals, Inc. shares are trading higher in after-market hours, currently positioned 11.58% above its 20-day moving average.

10 nov. 2026, 23:11 UTC

Regeneron Pharmaceuticals, Inc. shares advanced modestly in after-hours trading, reversing earlier losses and reaching the upper end of their one-month range.

9 nov. 2026, 21:07 UTC

Regeneron Pharmaceuticals reports positive results from its first-in-human trial of CIDEBsiRNA, with 93% of participants achieving significant liver fat reductions.

6 nov. 2026, 23:06 UTC

Regeneron Pharmaceuticals, Inc. shares are trading modestly lower in after-market hours, following a brief rise earlier in the session.

5 nov. 2026, 23:03 UTC

iShares Biotechnology ETF (IBB) is trading lower in after-market hours, with Regeneron Pharmaceuticals moving in sympathy with IBB amid mixed sector earnings results.

4 nov. 2026, 23:02 UTC

Regeneron Pharmaceuticals, Inc. shares are advancing in after-market hours, following a strong performance and remaining significantly above their 20-day moving average.

3 nov. 2026, 23:02 UTC

Regeneron Pharmaceuticals, Inc. shares declined in after-market trading, pulling back from a brief high to a notable low point following strong performance in prior sessions.

2 nov. 2026, 23:02 UTC

Regeneron Pharmaceuticals plans to webcast management participation at upcoming investor conferences, including Jefferies on November 17 and Evercore on December 1, 2026.

30 oct. 2026, 23:06 UTC

Regeneron Pharmaceuticals, Inc. is trading modestly lower in after-market hours, reversing a trend of three consecutive higher daily finishes.

29 oct. 2026, 23:03 UTC

Regeneron Pharmaceuticals, Inc. is trading higher in after-market hours, reflecting strong performance since Thursday's close and reaching a notable peak during the session.

28 oct. 2026, 23:02 UTC

Canaccord Genuity maintains its Buy rating on Regeneron Pharmaceuticals and raises the price target to $922, contributing to after-market gains.

26 oct. 2026, 20:07 UTC

Regeneron Pharmaceuticals extends its agreement with BARDA to supply $270 million in additional doses of Inmazeb, ensuring delivery through 2031.

23 oct. 2026, 20:51 UTC

Regeneron Pharmaceuticals Inc shares rose during after-market hours, moving higher alongside the broader market amid mixed economic indicators and falling U.S. Treasury yields.

22 oct. 2026, 23:51 UTC

Regeneron Pharmaceuticals Inc is trading higher in after-market hours, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

21 oct. 2026, 19:46 UTC

Regeneron Pharmaceuticals Inc shares fell.

20 oct. 2026, 23:02 UTC

Regeneron Pharmaceuticals Inc shares are declining in after-market trading, retracing earlier gains and positioned near the lower end of its recent trading range.

19 oct. 2026, 22:56 UTC

Regeneron Pharmaceuticals Inc. is trading modestly higher in after-market hours, maintaining gains above its 20-day moving average and near the upper end of its one-month range.

16 oct. 2026, 23:01 UTC

Regeneron receives positive opinion from the European Medicines Agency for an alternative dosing schedule for Libtayo® across all approved indications.

15 oct. 2026, 20:07 UTC

Regeneron Pharmaceuticals receives a UBS upgrade to Buy with a price target raised to $978, and partners with Sanofi to enhance Dupixent access in Canada.

14 oct. 2026, 20:02 UTC

Regeneron Pharmaceuticals Inc shares have risen sharply, supported by strong performance in the Biotechnology sector, remaining well above the previous close.

13 oct. 2026, 20:08 UTC

Regeneron Pharmaceuticals announces positive Phase 3 OPTIMA trial results for Pasatru™ in FOP patients, despite shares trading lower during Tuesday's session.

12 oct. 2026, 23:11 UTC

Regeneron Pharmaceuticals Inc is trading modestly higher in after-market hours, continuing a positive trend after three consecutive sessions of gains.

9 oct. 2026, 20:01 UTC

Regeneron Pharmaceuticals Inc is trading higher, having reached a peak earlier today while remaining below its 20-day moving average.

8 oct. 2026, 23:01 UTC

Regeneron Pharmaceuticals Inc is declining in after-market trading, moving lower since Thursday's close and approaching the lower end of its one-month range.

7 oct. 2026, 23:45 UTC

Regeneron Pharmaceuticals Inc traded roughly flat in after-market hours, retracing from a post-close peak and remaining below its 20-day moving average.

6 oct. 2026, 23:30 UTC

Regeneron Pharmaceuticals Inc. is trading modestly lower in after-market hours, continuing a downward trend and positioned near the lower end of its one-month range.

5 oct. 2026, 23:05 UTC

Regeneron Pharmaceuticals Inc saw a slight gain in after-market trading, following a flat regular session, but remains below its 20-day moving average.